06.10.2020 • News

J&J Said to Pay $100 Million to Settle Talc Suits

Johnson & Johnson (J&J) has agreed to pay in excess of $100 million to resolve more than 1,000 class action lawsuits claiming its talc-based baby powder caused their cancer, the Bloomberg news agency has reported.

Bloomberg’s sources said J&J has struck deals with several law firms, suggesting the New Jersey-based group was trying to get ahead of the mounting toll of lawsuits still pending. Up to now, it has dealt only with individual claims, winning some and appealing verdicts that went against it.

In May, with the official litigation count at 19,400 cases, J&J announced plans to pull the talc-based powder from the North American market and switch to only cornstarch-based powder while continuing to sell the talc-based version elsewhere.

No cases have been heard since March, due to coronavirus-related shutdowns, and the news agency said the group has used the hiatus to negotiate with lawyers. The litigation lull is due to end this month, however.

On Oct. 13, a court Oakland, California, is set to hear a factory worker’s claims that his mesothelioma diagnosis is related to talc exposure. The plaintiff, Rosalino Reyes III, who says he used the Johnson & Johnson baby powder for about 50 years, was diagnosed in 2019.

Bloomberg Intelligence estimated in July that settling all the outstanding cases could cost J&J as much as $10 billion. In a July securities filing the same month, the healthcare group said it had established an accrual primarily for defense costs and reserves for potential settlement of currently pending mesothelioma cases, but did not name a sum.

 

Author: Dede Williams, Freelance Journalist

Johnson & Johnson (J&J) has agreed to pay over $100 million to resolve more...
Johnson & Johnson (J&J) has agreed to pay over $100 million to resolve more than 1,000 class action lawsuits claiming its talc-based baby powder caused their cancer, Bloomberg reports. The news agency’s Intelligence arm estimates J&J could pay $10 billion to settle all cases. (c) Johnson & Johnson

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.